Localizaciones osteoarticulares de la sarcoidosis

Ungprasert, 2016, Clinical characteristics of sarcoid arthropathy: a population-based study, Arthritis Care Res (Hoboken), 68, 695, 10.1002/acr.22737 Kobak, 2016, The clinical characteristics of sarcoid arthropathy based on a prospective cohort study, Ther Adv Musculoskelet Dis, 8, 220, 10.1177/1759720X16670598 Visser, 2002, Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors, Ann Rheum Dis, 61, 499, 10.1136/ard.61.6.499 Sweiss, 2010, Rheumatologic manifestations of sarcoidosis, Semin Respir Crit Care Med, 31, 463, 10.1055/s-0030-1262214 Petursdottir, 2007, Clinical manifestation, prevalence and prognosis of sarcoid arthropathy. A nation wide study: the Icelandic Sarcoidosis Study, Sarcoidosis Vasc Diffuse Lung Dis, 24, 113 Alaoui, 2005, Osteoarticular manifestations of sarcoidosis, Presse Med, 34, 19, 10.1016/S0755-4982(05)83878-3 Thelier, 2008, Osteoarticular involvement in a series of 100 patients with sarcoidosis referred to rheumatology departments, J Rheumatol, 35, 1622 Ramos-Casals, 2004, Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases, Medicine (Baltimore), 83, 85, 10.1097/01.md.0000121237.98962.1e Oudejans, 2017, Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsies, J Pain Res, 26, 2057, 10.2147/JPR.S142683 Yanardağ, 2004, Bone cysts in sarcoidosis: what is their clinical significance?, Rheumatol Int, 24, 294, 10.1007/s00296-003-0370-8 Goussault, 2018, Ultrasound characterization of ankle involvement in Löfgren syndrome, Joint Bone Spine, 85, 65, 10.1016/j.jbspin.2017.03.004 Le Bras, 2014, Evaluation of ankle swelling due to Lofgren's syndrome: a pilot study using B-mode and power Doppler ultrasonography, Arthritis Care Res (Hoboken), 66, 318, 10.1002/acr.22099 Isdale, 1992, Synovial cysts and sarcoid synovitis, Br J Rheumatol, 31, 497, 10.1093/rheumatology/31.7.497 Kobak, 2014, The prevalence of sacroiliitis and spondyloarthritis in patients with sarcoidosis, Int J Rheumatol, 2014, 28945, 10.1155/2014/289454 Erb, 2005, An assessment of back pain and the prevalence of sacroiliitis in sarcoidosis, Chest, 127, 192, 10.1378/chest.127.1.192 Pavy, 2007, Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, 74, 338, 10.1016/j.jbspin.2007.04.001 Sezer, 2008, A co-occurrence of sarcoidosis and ankylosing spondylitis: a case report, Rheumatol Int, 28, 605, 10.1007/s00296-007-0483-6 Zhou, 2017, Clinical characteristics of patients with bone sarcoidosis, Semin Arthritis Rheum, 47, 143, 10.1016/j.semarthrit.2017.02.004 Sparks, 2014, Osseous sarcoidosis: clinical characteristics, treatment, and outcomes – experience from a large, academic hospital, Semin Arthritis Rheum, 44, 371, 10.1016/j.semarthrit.2014.07.003 Wilcox, 2000, Bone sarcoidosis, Curr Opin Rheumatol, 12, 321, 10.1097/00002281-200007000-00016 Grozdic Milojevic, 2016, FDG PET/CT in bone sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 33, 66 Mostard, 2012, F-18 FDG PET/CT for detecting bone and bone marrow involvement in sarcoidosis patients, Clin Nucl Med, 37, 21, 10.1097/RLU.0b013e3182335f9b Conte, 2015, Sarcoidosis with bone involvement mimicking metastatic disease at (18)F-FDG PET/CT: problem solving by diffusion whole-body MRI, Ecancermedicalscience, 9, 537, 10.3332/ecancer.2015.537 Lower, 1995, Prolonged use of methotrexate in sarcoidosis, Arch Intern Med, 155, 846, 10.1001/archinte.1995.00430080088011 Russell, 2013, Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy, Semin Arthritis Rheum, 43, 119, 10.1016/j.semarthrit.2012.10.008 Judson, 2008, Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial, Eur Respir J, 31, 1189, 10.1183/09031936.00051907 Hostettler KE1, 2012, Long-term treatment with infliximab in patients with sarcoidosis, Respiration, 83, 218, 10.1159/000328738 Utz, 2003, Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis, Chest, 124, 177, 10.1378/chest.124.1.177 Baughman, 2005, Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial, Chest, 128, 1062, 10.1016/S0012-3692(15)50471-6 Sweiss, 2014, Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 31, 46 Judson, 2014, Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis, Eur Respir J, 44, 1296, 10.1183/09031936.00000914 Belkou, 2008, Rituximab as a treatment alternative in sarcoidosis, Joint Bone Spine, 75, 511, 10.1016/j.jbspin.2008.01.025 Sweiss, 2014, Rituximab in the treatment of refractory pulmonary sarcoidosis, Eur Respir J, 43, 1525, 10.1183/09031936.00224513 Oshagbemi, 2017, Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis, Osteoporos Int, 28, 2859, 10.1007/s00198-017-4115-z Heijckmann, 2007, Bone turnover and hip bone mineral density in patient with sarcoisosis, Sarcoidosis Vasc Diffuse Lung Dis, 24, 51 Heijckmann, 2008, Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4 years follow-up study, Osteoporos Int, 19, 839, 10.1007/s00198-007-0513-y Saidenberg-Kermanac’h, 2014, Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients, Arthritis Res Ther, 16, R78, 10.1186/ar4519 Bours, 2016, Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort, Osteoporos Int, 27, 1603, 10.1007/s00198-015-3426-1 Bolland, 2015, Bone density is normal and does not change over 2 years in sarcoidosis, Osteoporos Int, 26, 611, 10.1007/s00198-014-2870-7 Adler, 2003, Glucocorticoid-induced osteoporosis in patients with sarcoidosis, Am J Med Sci, 325, 1, 10.1097/00000441-200301000-00001 Stern, 1980, Evidence for abnormal regulation of circulating 1 alpha, 25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism, J Clin Invest, 66, 852, 10.1172/JCI109924 Meyrier, 1985, Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxy vitamin D3 and 1,25-dihydroxy vitamin D3 and parameters of disease activity, Q J Med, 54, 269 Inui, 2001, Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis, Am J Med, 110, 687, 10.1016/S0002-9343(01)00724-0 Hamada, 1999, Bone mineral density and vitamin D in patients with sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 16, 219 Kamphuis, 2014, Calcium and vitamin D in sarcoidosis: is supplementation safe?, J Bone Miner Res, 29, 2498, 10.1002/jbmr.2262 Bolland MJ, 2013, Randomised controlled trial of vitamin D supplementation in sarcoidosis, BMJ Open, 3, e003562, 10.1136/bmjopen-2013-003562 Baughman, 2013, Calcium and vitamin D metabolism in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 30, 113 Mahévas, 2009, Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients, Medicine, 88, 98, 10.1097/MD.0b013e31819de50f Gonnelli, 1997, Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients, Calcif Tissue Int, 61, 382, 10.1007/s002239900352 Challal, 2016, Teriparatide for osteoporosis in patients with sarcoidosis: report on risk-benefit ratio in four cases, Joint Bone Spine, 83, 344, 10.1016/j.jbspin.2015.11.007